ストックスクリーナーアプリを入手
188.01
2.60%
-5.02
プレマーケット:
189.27
1.26
+0.67%
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca Upbeat on Growth as 2025 Profit, Revenue Rise Amid 'Excellent' Pipeline Delivery - Yahoo Finance UK
AstraZeneca (AZN) Projects Revenue Growth and Core Tax Rate Outl - GuruFocus
AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 -- Update - marketscreener.com
AstraZeneca’s growth engine stays on track despite cost pressures - Proactive financial news
AstraZeneca profit jumps as cancer drug sales grow - Yahoo Finance UK
AstraZeneca (Q4 Results): steady progress - Hargreaves Lansdown
AstraZeneca PLC Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
AstraZeneca Sees Further Growth, Lifted by Cancer Drugs - bloomberg.com
AstraZeneca profits surge 40% on strong demand for cancer treatments - business-live.co.uk
Trending tickers: TSMC, Oracle, AstraZeneca, Kering and Tui - Yahoo Finance UK
Astrazeneca Q4 Core Earnings, Revenue Rise; Full-Year Outlook Set -- Shares Up Pre-Bell - marketscreener.com
FTSE 100 falls as BP slide outweighs AstraZeneca - marketscreener.com
AstraZeneca profits jump by 40% amid strong demand for cancer drugs - Yahoo Finance UK
Strong cancer drug sales boost AstraZeneca earnings - Financial Times
Astrazeneca: Q4 Earnings Snapshot - kens5.com
BP halts buybacks; AstraZeneca lifts annual earnings - marketscreener.com
AstraZeneca Q4 And FY 2025: Strong Sales Growth And Pipeline Momentum - DirectorsTalk Interviews
Annual sales, profits jump at AstraZeneca - Sharecast.com
AstraZeneca Forecasts Continued Growth on Pipeline Strength - marketscreener.com
AstraZeneca forecasts 2026 sales, profit growth as Q4 meets expectations By Investing.com - Investing.com UK
AstraZeneca expects 2026 core EPS to increase by low double-digit percentage - marketscreener.com
AstraZeneca Forecasts Stronger Profits in 2026 on Cancer Drug Momentum - FXLeaders
AstraZeneca Logs Higher FY25 Profit, Revenue - marketscreener.com
AstraZeneca : Full Year and Q4 2025 results - marketscreener.com
Earnings Flash (AZN.L) AstraZeneca PLC Posts FY25 EPS $6.54 - marketscreener.com
AstraZeneca PLC Delivers Promising Financial Outlook - Devdiscourse
AstraZeneca's Q4 revenue up 4% to $15.5B - breakingthenews.net
AstraZeneca's 2026 Profit Growth Forecast and Market Insights - Global Banking & Finance Review®
Drugmaker AstraZeneca forecasts sales and profit growth in 2026 - marketscreener.com
AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growth - Proactive Investors
AstraZeneca forecasts steady growth in 2026 on strong cancer drug demand, shares rise - Reuters
Full Year and Q4 2025 results - AstraZeneca
AstraZeneca PLC (LSE:AZN) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? - TradingView
AstraZeneca earnings up next after NYSE debut, China expansion By Investing.com - Investing.com UK
A Look Ahead: AstraZeneca's Earnings Forecast - Benzinga
AstraZeneca bets big on China - fDi Intelligence
AstraZeneca's Evinova Enters Clinical Development AI Partnership Deal - marketscreener.com
Is AstraZeneca PLC Depositary Receipt stock risky to hold nowJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
AstraZeneca PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights- AZN - accessnewswire.com
AstraZeneca stock price: What could move AZN next week as earnings loom - TechStock²
AstraZeneca’s Stock Under Pressure: Is AZN’s Recent Slide A Buying Opportunity Or A Warning Sign - AD HOC NEWS
Deutsche Bank Maintains Sell on AstraZeneca PLC (AZN) Feb 2026 - Meyka
Week ahead: AstraZeneca, Unilver, BP results due - Sharecast.com
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance - FinancialContent
Stocks to watch next week: BP, Barclays, AstraZeneca, Airbnb and Coinbase - Yahoo Finance UK
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.
AstraZeneca’s Precision Oncology Approach Applies To Deal, Portfolio Decisions - Citeline News & Insights
AstraZeneca (AZN) Among Major Drugmakers in Focus Amid Trump's D - GuruFocus
AstraZeneca opens on NYSE, expands in China - Cambridge Independent
Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? - Yahoo Finance
AstraZeneca Full-Year 2025 Earnings Preview: 10 February 2026 - IG Group
AstraZeneca PLC (NASDAQ:AZN) announces strategic collaboration agreement with CSPC Pharmaceuticals - MSN
J.P. Morgan Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Cuts Target Price to $220.07 - 富途牛牛
Why AstraZeneca (AZN) dipped more than broader market today - MSN
Why Astrazeneca (AZN) Dipped More Than Broader Market Today - Yahoo Finance Singapore
AstraZeneca stock soared 103% Monday, holding at high level. Gets rating upgrade. - MSN
AstraZeneca PLCUpdate on Saphnelo subcutaneous administration - Research Tree
AstraZeneca (AZN) Faces FDA Setback for Lupus Drug Saphnelo - GuruFocus
Jim Cramer Says "I Like AstraZeneca Very Much" - Finviz
AstraZeneca (AZN) Stock Surges Over 100% - GuruFocus
Astrazeneca plc Provides Update on US Regulatory Review of Saphnelo Subcutaneous Administration in Systemic Lupus Erythematosus - marketscreener.com
Astrazeneca doubles down on China with $15B+ investments - BioWorld MedTech
Jim Cramer says "I like AstraZeneca very much" - MSN
Jim Cramer Says “I Like AstraZeneca Very Much” - Insider Monkey
AstraZeneca’s AZD4063 Edges Forward in Rare Genetic Cardiomyopathy Trial: What Investors Should Watch - TipRanks
FDA launches ‘PreCheck’ program; AstraZeneca, Acadia drugs set back - BioPharma Dive
Eyes on Asia: SangeneBio, Newsoara, AstraZeneca - BioXconomy
3.51%
0.40%
大文字化:
|
ボリューム (24 時間):